Venture Life Share Discussion Threads

[hydrus] 24/10/2017 18:09

With TET I have no idea if there is further downside in the short term. Who knows it may get cheaper but I'm comfortable paying 20 times earnings for a high quality company with good long term growth prospects. There are companies with I would say similar growth prospects currently, on PE ratios of 35 plus.

[hydrus] 24/10/2017 17:55

My understanding is that most of their revenue is generated from manufacturing and selling ingredients, which are then used in various products. Therefore I assume they receive ongoing revenues whenever a company needs the ingredients to manufacture more products.

[attrader] 24/10/2017 17:19

Hydrus, looking at TET.. do you know how they get paid for their work? Do they charge one off product development fee ? Or is it based on royalities ?

[hydrus] 24/10/2017 17:02

ZOO motoring on again. It's currently supporting my portfolio nicely which is only 2% off ATH despite a few recent weak performances in the quality/growth part of portfolio. All down to ZOO really.

[panic investor] 24/10/2017 13:47

KWS placing away at 1400p - impressive stuff

[janeann] 24/10/2017 13:29

Added a few PCTN; decent yield c 4%, premium to NAV now much reduced and expecting ex dividend date very early Nov although cant find it.

[modform] 24/10/2017 12:42

KWS, Looks very bullish panic

[panic investor] 24/10/2017 12:35

Anybody spotted KWS RNS :-)

[hydrus] 24/10/2017 12:33

Topped up both EAH and TET this morning. I think TET is looking decent value and I hope EAH will surprise on the upside. Broker EPS target seems conservative.

[modform] 24/10/2017 12:10

dacian, this might be of interest with the possible impact on VLTY. Thanks to cfro for the link, no advice is intended.

[apad] 23/10/2017 20:30

BVXP

Paton:
maynardpaton.com/2017/10/16/bioventix-outstanding-2017-results-but-cagey-troponin-remarks-may-leave-29x-pe-rather-exposed/#comments

has picked up (in the replies) the importance of the lack of currency hedging.

apad

[apad] 23/10/2017 17:20

Decent Beddard article on ABC:
www.sharescope.co.uk/richardbeddard_article176.jsp

Misses one point that I still believe is valid: that the more successful work is done on an antibody the more valuable it becomes.
When ABC used to publish more useful data I noticed that some antibodies were dumped.
So, if this hypothesis is correct their product portfolio increases in value year on year.

apad

[apad] 23/10/2017 16:58

I haven't, Big7.
I'm trying to stick to my last.
No good at trading and not dealing with money I need to live.
Also, my holdings are quite large for illiquid caps.

Looked up FARN to buy some more today and IB were offering 70 shares!

I'll probably still sell RWS when things have settled, but am giving it another look. 470 above the 425 humongous placing seems to imply some confidence in the market and the volumes traded don't look large.
Maybe there is something I missed?

TRAK rns has stimulated a positive Stocko report which has stimulated the price. Need a lot of faith to believe that things have changed :-)

apad

[redartbmud] 23/10/2017 16:41

Rws is a mouthful. I am watching with interest. Insufficient to cost effectively topslice.

red

[big7ime] 23/10/2017 16:14

Just curious APAD, have you made any sales recently? I saw you made some purchases and know you're not a trader but some of the froth has been coming off lately and wondered if you had been tempted?

As you know I have been selling, building cash and moving into oil and mining sectors

[hydrus] 23/10/2017 14:10

G4M revenue growth is good. I have a much smaller holding there than I once did after buying in under £3 but still have some confidence in them. My nervousness is that they sell discretionary items and in a recession I can't imagine people rush out and replace musical instruments.

[panic investor] 23/10/2017 13:33

A point about bullet proof rns's G4M just now !

[lauders] 23/10/2017 11:02

Back from a business and holiday trip to Africa and see that BVXP is now cheaper than it was before I left. Tempted to top-up before the dividend but may just buy 71p lower or more (?) on the ex-dividend day or shortly after. The latter may be a better decision as I can see it going a bit lower with some momentum and the ex-dividend date may be the momentum trigger. I see some are hoping for around 2000p. Other than that SDX is also down even after good drilling results. Must be because I hold them LOL!

[apad] 23/10/2017 10:44

Thanks red. I'd seen the update but not the presentation.

RWS - still a big mouthful. I'll have a look at it again.

apad

[redartbmud] 23/10/2017 10:23

Rws
He ran numbers on model. Studied detail. Happy with outcome. Knows Bride reasonably well. Sound judgment. Few companies realty with. Monitors closely. Ruthless chopper when story changes.

red

Edit Brode bloody phone!

[redartbmud] 23/10/2017 10:06

Rsw
In the presentation stated that upgraded additive machine well received in the marketplace. Getting orders.

red

[janeann] 23/10/2017 09:57

RSW 20 oct .... perhaps you missed it?

Renishaw plc

Trading update

20th October 2017

Ahead of the AGM being held at noon today, we are providing a short trading update as follows:

Renishaw plc, the global high-precision metrology and healthcare manufacturer, publishes this trading update for the three months ended 30th September 2017. It contains unaudited information that covers the first quarter and the period since.

Trading activity

Continuing operations

First quarter
2018

First quarter
2017

Change


Metrology

£137.1m

£108.9m

+26%


Healthcare

£5.2m

£4.0m

+30%


Total Revenue

£142.3m

£112.8m

+26%




Adjusted* Profit before tax


£35.8m


£15.1m


+137%


Statutory Profit before tax

£36.9m

£10.7m






Revenue from continuing operations for the first quarter of the current financial year was £142.3m, a growth of 26% over the £112.8m for the corresponding period last year. Revenue benefited due to a number of large orders from Far East customers in the consumer electronics markets. We experienced underlying growth at constant exchange rates of 20% with growth in all regions.



In our metrology business revenue amounted to £137.1m compared to £108.9m last year, with an underlying growth at constant exchange rates of 20%. Revenue in our healthcare business was £5.2m compared with £4.0m last year, a growth of 29% at constant exchange rates.



Restated and adjusted* profit before tax from continuing operations for the first quarter amounted to £35.8m compared with £15.1m last year.



Financial position

The Group balance sheet remains strong with net cash balances of £82.6m as at 30th September 2017 (30th June 2017: £64.8m), including an escrow account of £12.9m (30th June 2017: £12.9m) which provides additional security for the UK defined benefit pension scheme.


Outlook

The Board remains confident in the future prospects of the Group and of achieving good growth in both revenue and profit in this financial year.

The results for the half year ending 31st December 2017 will be released on 25th January 2018.

[apad] 23/10/2017 08:40

Nothing recent on RSW that I know of, red?

Did your contact give a reason for his view on RWS?
If not please ask :-)

Enjoy the Fawlty Towers rain! I'm driving to Bournemouth tomorrow.

At these times my policy not to take into account the macro environment puts me under strain, Panic:-)

apad

[panic investor] 23/10/2017 06:11

Been worried about RWS but will give the BOD benefit of the doubt I sold BVXP at 8am results day too many unknowns now for my liking, probably proved wrong though.APAD - all it takes now is one negative word in a brilliant RNS to bring a stock down - been taking a lot off the table before updates - this does go wrong though obviously - take RWS as an example